Back to Newsroom

Ocata Therapeutics Receives Regulatory Guidance from European Medicines Agency

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata”; NASDAQ: OCAT), a leader in the field of regenerative ophthalmology, today announced that the company has received written formal guidance from the European Medicines Agency (EMA) related to the advancement of its Retinal Pigment Epithelium Program (RPE) into a pivotal clinical trial for Stargardt’s Macular Degeneration (SMD).

Click here to read the full release